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general transcriptional machinery, such as TAFs. Third,
a number of phosphorylation sites have been identified
in the vicinity of this region that are highly likely to be
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How does MDM2 mediate p53 degradation? There
have been a number of attempts to address this ques-
The p53 tumor suppressor protein transmits signals aris- tion. Honda et al. (1997) reported that MDM2 can func-
ing from various forms of cellular stress, including DNA tion as an E3 ubiquitin ligase, a result that is consistent
damage, hypoxia, and nucleotide deprivation, to genes with evidence that MDM2 destabilization of p53 is re-
and factors that induce cell cycle arrest and cell death. duced in the presence of proteasome inhibitors (Haupt
We can thus define events as being upstream or down- et al., 1997; Kubbutat et al., 1997). Grossman et al. (1998)
stream of p53. The endpoint of the upstream compo- have provided evidence that MDM2 needs to bind to
nent of this pathway is that levels of the p53 protein the p300 transcriptional coactivator/histone acetylase
are dramatically increased through posttranscriptional in order to mediate degradation of p53. Adding further
mechanisms, often by one or two orders of magnitude. complexity to this issue, Roth et al. (1998) have shown
There is also evidence that in addition to elevating p53 that MDM2 shuttles p53 from the nucleus to the cyto-
levels, such signals convert the protein from an inert plasm where it is then degraded. We can undoubtedly
form to one that is activated for sequence-specific tran- expect further clarification of the mechanism of MDM2-
scriptional activation (reviewed in Ko and Prives, 1996). mediated degradation of p53 in the near future.
Stress signals are not the only means by which p53 Given the above information, it has become clear that
becomes stabilized. The DNA viruses SV40 and adenovi- one way to stabilize and activate p53 in cells is by in-
rus encode gene products, T antigen and E1a, respec- terfering either with the interaction between MDM2 and
tively, that lead to increased quantities of p53 protein p53 or with the ability of MDM2 to target bound p53 for
in cells. Moreover, under some conditions expression degradation. How might the p53±MDM2 interaction be
of cellular factors such as Myc or Ras can also result regulated? At least two mechanisms can be envisaged,
in p53 induction. Although this might seem at odds with one through changes in p53 due to covalent modifica-
the outcome of transformation caused by viral or cellular tion, and the other through noncovalent regulators of
oncogenes, viruses and cells have evolved several ways the p53±MDM2 association. It is now apparent that both
to counteract the growth suppression functions of in- mechanisms can be identified under experimental con-
duced p53. The downstream component of the p53 ditions: DNA damage±induced phosphorylation of p53
pathway has been relatively well explored, and many can attenuate the p53±MDM2 interaction, and the prod-
transcriptional targets of p53 have been identified and uct of the alternate reading frame (ARF) located within
characterized, including the gene encoding the CDK
the p16INK4A locus (murine p19ARF, human p14ARF) can bind
inhibitor, p21. By contrast, the upstream component
to MDM2 and prevent its destruction of p53. Interest-
had been quite elusive until recently, and a number of
ingly, these two mechanisms appear to be entirely sepa-
significant breakthroughs have now provided insight
rate and independent from each other, and regulatedinto this aspect of p53. While there are likely to be multi-
through distinct signaling pathways.ple modes of induction of p53, current knowledge sug-
Signaling through Covalent Modification of p53gests that diverse upstream signals funnel into a single
The phosphorylation status of a protein can have pro-critical interaction, namely that between p53 and its
found consequences upon its function in cells. Givennegative regulator, MDM2.
that p53 is known to be responsive to a variety of stressp53 and MDM2
signals, considerable attention has focused on the de-The ability of p53 to either restrain or kill a cell must be
termination of phosphorylation sites within the N-termi-reigned in under normal conditions. MDM2 accom-
nal activation region and the C-terminal regulatory do-plishes this in two ways: as a result of its physical inter-
main (Figure 1). A number of human p53 sites have beenaction with p53, MDM2 both represses p53 transcrip-
identified that are known to be phosphorylated in vivo,tional activity and mediates the degradation of p53. The
and several kinases have been identified that can phos-latter function of MDM2 was revealed when it was dis-
phorylate these same sites in vitro. However, evidencecovered that overexpression of MDM2 results in re-
is only indirect at present for utilization of some of theduced quantities of coexpressed p53, and that disrup-
N-terminal sites.tion of the p53±MDM2 interaction by mutation results
One key technical breakthrough in determining stress-in both activation and accumulation of p53 (Haupt et
induced changes in phosphorylation has been the use ofal., 1997; Kubbutat et al., 1997). The region on p53 with
phosphorylation site-specific antibodies. Such reagentswhich MDM2 interacts (residues 17±27) is interesting for
have enabled the detection of specific constitutive orseveral reasons: First, it is one of the segments of p53
dynamic phosphorylation events with a sensitivity andthat is highly conserved not only among different spe-
rapidity that was previously impossible. Using such ancies, but even among some p53-related family mem-
antibody, Ser15 was the first human p53 site shown tobers, such as p73. Second, this portion of p53 is located
be inducibly phosphorylated after DNA damage (Shiehwithin the transcriptional activation region, which is re-
quired for the interaction of p53 with components of the et al., 1997; Siliciano et al., 1997). This site is a known
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will be important to continue to explore how N-terminal
phosphorylation and kinases affect p53 stability and
interaction with MDM2.
Stress-induced changes are not relegated solely to
the N terminus of p53, and several recent studies have
reported alterations in C-terminal modification sites.
Two groups reported that UV but not IR induces phos-
phorylation of murine Ser389 (Kapoor and Lozano, 1998;
Lu et al., 1998). Thus, as is the case with ATM, different
types of DNA damage are relayed through discrete path-
ways to p53. Not only kinases are signaling targets:
Waterman et al. (1998) made the interesting observationFigure 1. Stress-Induced Modifications of Human p53 Protein
that Ser376, previously shown to be a protein kinase-CDomains or regions of p53 indicated are as follows: activation do-
(PK-C) site, is actually dephosphorylated after IR in nor-main (AD), residues 1±60; growth suppression PXXP region (PD),
mal but not AT2 cells, implying that a stress-responsiveresidues 63±97; DNA-binding domain (DBD), residues 100±300;
linker region (L), residues 305±323; tetramerization domain (TD), phosphatase may also regulate p53 modification. Loss
residues 323±356; and basic C-terminal regulatory region (BD), resi- of phosphate at this residue is correlated with both bind-
dues 363±393. Sites at N terminus include potential sites (Ser6, -9 ing of p53 to 14-3-3 proteins and activation of sequence-
and -20, and Thr18) and sites known to be phosphorylated in vitro
specific DNA binding. Furthermore, DNA damage-induc-by ATM, DNA-PK, or the cyclin-activating kinase complex, CAK, as
ible acetylation of a C-terminal residue (Lys382) wasindicated. C-terminal phosphorylation sites for CDK, PK-C and CKII
recently reported (Sakaguchi et al., 1998), showing thatprotein kinases, and PCAF and p300 acetyl transferases are indi-
cated. Altered modification sites after DNA damage are shown in signaling is not exclusive to changes in phosphorylation.
yellow for phosphorylation sites and purple for acetylation site. Gray How might these C-terminal modifications affect p53's
regions indicate highly conserved regions on p53, including region function? As mentioned above, it has been known for
I, which interacts with MDM2.
some time that p53 can be isolated in a form that is
virtually incapable of binding to DNA, due to the fact
substrate for the DNA-activated protein kinase (DNA- that the highly basic p53 C terminus can negatively regu-
PK). Although it is unclear whether DNA-PK phosphory- late the central sequence-specific DNA-binding region.
lates p53 directly in vivo, the recent observation of Woo Phosphorylation of either cyclin-dependent kinase (CDK),
et al. (1998) showing that p53 is inert as a transcriptional PK-C, or casein kinase II (CKII) sites within this region
activator in cells lacking detectable DNA-PK activity relieves autorepression of the central domain by the C
suggests that indeed DNA-PK is upstream of p53 and terminus. More recently it was also reported that ace-
is required for its transcription function. Ser15 has also tylation of p53 at C-terminal lysine residues accom-
been shown to be phosphorylated by another kinase, plishes a similar result (Gu and Roeder, 1997; Sakaguchi
the product of the ATM gene (Banin et al., 1998; Canman et al., 1998). Both phosphorylation and acetylation are
et al., 1998), that is defective in patients with ataxia likely to work by counteracting the effects of the highly
telangiectasia (AT), a syndrome characterized by pleio- positively charged C terminus. However, noncovalent
tropic phenotypes including extreme sensitivity to ioniz- modifiers such as antibodies, short single strands of
ing radiation. Importantly, ATM kinase activity is in- DNA, or the redox-repair protein, REF1, can also activate
creased after DNA damage, providing a tantalizing hint latent p53. Since these experiments have for the most
that ATM may phosphorylate p53 in vivo. Phosphoryla- part been performed in vitro, it has been gratifying to
tion of Ser15 is delayed in cells from AT patients (AT2 identify altered modifications of p53 in vivo after stress
cells) after gamma irradiation (IR) but not UV, suggesting signals that might lead to its activation. The fact that
that ATM is important for signaling to p53, but in a the C terminus is subjected to multiple changes after
DNA damage±specific manner (Siliciano et al., 1997). DNA damage lends credence to the concept that p53
Nevertheless, in AT2 cells p53 does eventually become can exist in a latent state until it is needed to function
phosphorylated at Ser15 after IR, indicating either that as a regulator of cell growth or death. Whether any given
other kinases can substitute for ATM or that the kinetics modification results in selective activation of different
of the bona fide primary Ser15 kinase (as yet unidenti- p53 functions or outcomes will be of considerable inter-
fied) is regulated by ATM kinase. est in the future. Furthermore, it will be important to
That Ser15 is a target for different protein kinases determine whether changes in p53 conformation due
suggests that modification of this site is important for to C-terminal modification will be propagated to the
altering p53 after DNA damage. Indeed, Shieh et al. N-terminal region and thus affect its interaction with
(1997) found that DNA damage-induced phosphoryla- MDM2.
tion at Ser15, which lies at the N-terminal border of The Discovery of ARF Explains How
the MDM2 interaction region, weakens both the p53 Oncogenes Regulate p53
association with MDM2 and the ensuing ability of MDM2 How p53 becomes stabilized by viral and cellular onco-
to repress transcriptional activation by p53. This obser- genes remained a complete mystery until quite recently.
vation provides a paradigm for how DNA damage± The discovery of the product of an ARF within the p16INK4a
induced phosphorylation might lead to stabilization and locus encoding an inhibitor of cyclin D±associated CDKs
activation of p53. Additional sites within the N terminus has led to a flurry of studies that have provided a quan-
are likely to be inducibly phosphorylated (Siliciano et tum leap in our understanding of how p53 stabilization
might occur. Murine ARF-null mice are highly tumoral., 1997; Sakaguchi et al., 1998; see Figure 1), and it
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Figure 2. Oncogenes and Stress Signals In-
dependently Activate p53 through MDM2
prone, and their mouse embryo fibroblasts, like those Stanchina et al., 1998). Indeed, the E1a result beautifully
connects the Rb pathway to p53: by counteracting thelacking p53, are immortal (Kamijo et al., 1997). Overex-
ability of Rb to repress E2F, E1a promotes ARF activa-pression of p19ARF in wild-type but not p532/2 cells
tion and consequent p53 stabilization. Consistent withcauses cell cycle arrest, suggesting that ARF acts up-
the observation that the p53 DNA damage±responsivestream of p53 (Kamijo et al., 1998). Moreover, in wild-
pathway is intact in ARF2/2 cells, de Stanchina et al.type cells ARF overexpression leads to increased levels
(1998) have found that p53 phosphorylation on Ser15of p53 and the p53 target gene, p21 (Kamijo et al., 1998).
occurs in DNA-damaged, but not E1A-expressing, cells.Strikingly, however, in ARF2/2 cells p53 induction and
Not only viral but also cellular oncogenes can regulatea p53 cellular response to DNA damage is intact (Kamijo
p53 through ARF. Zindy et al. (1998) have demonstratedet al., 1997). Thus, under some conditions ARF is re-
that Myc, presumably working through an independentquired to induce p53, but its regulation of p53 is separate
mechanism, can induce ARF. Intriguingly, Myc overex-and independent from DNA damage±induced signaling
pression in mouse embryo fibroblasts rapidly leads toto the p53 protein.
the appearance of variants that lose either ARF or p53How does ARF induce p53? A number of studies have
function giving rise to immortal cells that are resistantrevealed direct physical interactions between ARF, p53,
to Myc-induced apoptosis and that can be transformedand MDM2. Several groups (Kamijo et al. 1998; Pomer-
by oncogenic Ras alleles alone (Zindy et al., 1998). It isantz et al., 1998; Stott et al., 1998; Zhang et al., 1998)
interesting to speculate that immortalization of primaryhave found that ARF binds to MDM2 and that trimeric
fibroblasts by genes like E1a and Myc and their cotrans-complexes between p53, MDM2, and ARF can form in
formation by Ras may depend in part on the ability ofvivo. The N-terminal 62 amino acids of murine ARF are
Myc and E1a to enforce selection of cells that havesufficient for it to bind to the C-terminus of MDM2 within
dismantled the ARF±p53 checkpoint. This conjecture isa region not required for MDM2 association with p53
supported by the observation that overexpression of(Kamijo et al. 1998; Zhang et al., 1998). However, conclu-
p19ARF counteracts the ability of Myc and Ras to trans-sions about the consequences of these interactions dif-
form wild-type but not p532/2 cells (Pomerantz et al.fer among the different investigators: Zhang et al. (1998)
1998). It is anticipated that yet additional pathways willreported that ARF can itself target MDM2 for degrada-
connect oncogenes to p53 through ARF, and a recenttion. The other studies, however, do not suggest this as
report from Palmero et al. (1998) suggests that Ras maya mechanism for how the association of ARF with MDM2
also be involved in this process.
leads to increased quantities of p53, and more work will
The Complexity of p53 Circuitry
be required to reveal the mode(s) of action of ARF on
The studies described above are but another chapter
MDM2 and p53. in the continuing saga of deciphering p53. We now have
With the excitement following the discovery that ARF further evidence that p53, a key cellular regulator, is
regulates p53, researchers were keen to unearth how under the control of MDM2. But intricate circuitry is at
ARF is itself triggered in cells. It is now clear that ARF is play here: p53 itself is instrumental in upregulating its
induced by viral and cellular oncogenes, thereby counter- inhibitor, MDM2, and also downregulating its activator,
ing hyperproliferative signals by inducing p53-depen- ARF, as depicted in Figure 2. It is well established that
dent apoptosis. We can envisage a cellular pathway in MDM2 is itself a transcriptional target of p53 that is
which ARF levels are regulated by the retinoblastoma induced after p53 becomes stabilized and activated.
protein, Rb, another well-studied tumor suppressor (Fig- There is now evidence that p53 downregulates ARF un-
ure 2). Normally, hypophosphorylated Rb binds and der normal conditions (Stott et al., 1998). Thus, by inter-
blocks the activity of members of the E2F family of acting with MDM2 and inhibiting ARF expression, p53
transcription factors, including E2F1. The E2Fs function levels are kept low during normal conditions. After
to activate a number of genes required for passage into stress, modification of the p53 protein prevents or dis-
and through S phase. Bates et al. (1998) now report that rupts the p53±MDM2 interaction, while as a result of
E2F1 induces ARF expression most likely through its oncogene imbalance, ARF is induced and MDM2 is pre-
ability to activate the ARF promoter. The findings in vented from destabilizing p53. The outcome in both
two current papers using mouse models, that E2F1 is cases, though, is increased and activated p53 protein.
instrumental in regulating p53-mediated apoptosis (Pan Overlaid on the p53±MDM2 binary switch and its regula-
et al., 1998; Tsai et al., 1998), fit nicely with this obser- tors is circuitry connecting the two tumor suppressors,
vation. p53 and Rb. Activation of p53 after DNA damage leads
DNA tumor virus products can associate with Rb, dis- to G1 arrest that, through p21, occurs by maintenance
rupting its ability to block passage of cells through G1 of active unphosphorylated Rb, which in turn restrains
phase. It has now been shown that E1a induces ARF E2Fs. Thus, in this situation p53 can be seen as up-
expression in cells, and importantly, the ability of E1a stream of Rb. E1a and T antigen can bind to and inacti-
vate Rb, and both can stabilize p53 through the ARFto stabilize p53 is absent in ARF2/2 fibroblasts (de
Cell
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Palmero, I., Pantoja, and Serrano, M. (1998). Nature 395, 125±126.pathway. Here the case is reversed and now Rb be-
Pan, H., Yin, C., Dyson, N., Harlow, E., Yamasaki, L., and Van Dyke,comes the regulator of p53. The fact that the INK4A
T. (1998). Mol. Cell 2, 283±292.locus, frequently deleted in tumors, encodes overlap-
Pomerantz, J., Schreiber-Agus N., Liegeois, N.J., Silverman, A., Al-ping regulators of Rb and p53, further attests to the
land, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.W., et al.intimate relationship between these two tumor suppres-
(1998). Cell 92, 713±723.
sors, long suspected by DNA tumor virologists to be
Roth, J., Dobbelstein, M., Freedman, D.A., Shenk, T., and Levine,intertwined.
A.J. (1998). EMBO J. 17, 554±564.
Future Directions
Sakaguchi, K., Herrera, J.E., Saito, S., Miki, T., Bustin, M., Vassilev,
As is often the case with new discoveries, new questions A., Anderson, C.W., and Appella, E. (1998). Genes Dev., in press.
are posed: What are the protein kinases involved in Stott, F., Bates, S.A., James, M., McConnell, B.B., Starborg, M.,
phosphorylating p53 sites that regulate its interactions Brookes, S., Palmero, I., Hara, E., Vousden, H., and Peters, G. (1998).
with MDM2? Do different forms of genotoxic stress acti- EMBO J. 17, 5001±5014.
vate discrete upstream kinase signaling cascades and Shieh, S.-Y., M.Ikeda, Taya, T., and Prives, C. (1997). Cell 91,
325±334.result in different outcomes, such as apoptosis versus
cell cycle arrest? How does phosphorylation of N-termi- Siliciano, J.D., Canman, C.E., Taya,Y., Sakaguchi, K., Appella, E.,
and Kastan, M.B. (1997). Genes Dev. 11, 3471±3481.nal sites affect p53's interaction not only with MDM2,
Tsai, K.Y., Hu, Y., Macleod, K.F., Crowley, D., Yamasaki, L., andbut also with transcription factors and with its DNA
Jacks, T. (1998). Mol. Cell 2, 293±304.sites? How do Myc and Ras signal to ARF? The model
Waterman, M.J., Stavridi, E.S., Waterman, J.L., and Halazonetis,presented in Figure 2, suggesting that release of E2F is
T.D. (1998). Nat. Genet. 19, 175±178.sufficient to stabilize p53, is likely to be an oversimplifi-
Woo, R.A., McLure, K.G., Lees-Miller, S.P., Rancourt, D., and Lee,cation. Since E2F activity is liberated during transit to
P.W.K. (1998). Nature 394, 700±704.S phase, how is p53 checkpoint function reigned in
Zhang, Y., Xiong, Y., and Yarbrough, W.G. (1998). Cell 92, 725±734.during normal passage of cells through the cycle? Onco-
Zindy, F., Eischen, C.M., Randle, D.H., Kamiho, T., Cleveland, J.L.,genes may not only work to relieve repression of E2F;
Sherr, C.J., and Roussel, M.F. (1998). Genes Dev. 12, 2424±2433.perhaps they can also prevent downregulation of ARF
by p53. Are there signaling and stabilization pathways
to p53 that are separate from the two outlined in Figure
2? How does p53 get back to ground state once stabi-
lized by either ARF or DNA damage? And perhaps the
most important question of all: can these discoveries
be used for therapeutic purposes? Answers to these
and related questions are likely to keep many of us busy
for the forseeable future.
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